XBRL SEC Pilot Pfizer Inc.

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CwBcHWbEMX1ErqzYg/ZaoQZl/2Jh9YAK7GjZYqYPw2jTy/iLr1OkTXqsgLFUoa3i mu8QvohXKPJLdC0tEyUTCw== 0000078003-06-000337.txt : 20061211 0000078003-06-000337.hdr.sgml : 20061211 20061211152845 ACCESSION NUMBER: 0000078003-06-000337 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 7 CONFORMED PERIOD OF REPORT: 20061211 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20061211 DATE AS OF CHANGE: 20061211 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 061268353 BUSINESS ADDRESS: STREET 1: 235 E 42ND ST CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2125732323 MAIL ADDRESS: STREET 1: 235 E 42ND ST CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 8-K 1 k8pfe-20061001.htm XBRL PFIZER 8-K XBRL SEC Pilot Pfizer Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: December 11, 2006 Date of earliest event reported: December 11, 2006
PFIZER INC. (Exact name of registrant as specified in its charter)

DELAWARE (State or other jurisdiction of incorporation)	1-3619 (Commission File Number)	13-5315170 (I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017 (Address of principal executive offices) (zip code) (212) 573-2323 (Registrant's telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:

[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

Exhibit 100 to this Current Report on Form 8-K contains documents formatted in XBRL (eXtensible Business Reporting Language) with information from Pfizer Inc.'s Quarterly Report on Form 10-Q for the quarter ended October 1, 2006, filed with the Securities and Exchange Commission (SEC) on November 3, 2006. The information formatted in XBRL includes the (i) Condensed Consolidated Statements of Income for the three and nine months ended October 1, 2006 and October 2, 2005, (ii) Condensed Consolidated Balance Sheets at October 1, 2006 and December 31, 2005, and (iii) Condensed Consolidated Statements of Cash Flows for the nine months ended October 1, 2006 and October 2, 2005.

Users of this data are advised pursuant to Rule 401 of Regulation S-T that the financial information contained in the XBRL-Related Documents is unaudited and these are not the official financial statements of Pfizer Inc. as filed with the SEC. The purpose of furnishing these XBRL formatted documents is solely for the purpose of participation in the SEC's voluntary XBRL pilot program to test the related format and technology and, as a result, investors should continue to rely on the official filed version of the furnished documents and not rely on the information in this Current Report on Form 8-K, including Exhibit 100, in making investment decisions.

In accordance with Rule 402 of Regulation S-T, the information in this Current Report on Form 8-K, including Exhibit 100, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d)	Exhibits

	The following exhibits are furnished herewith:

	Exhibit Number	Exhibit Description

	100	The following financial statements from Pfizer Inc.'s Quarterly Report on Form 10-Q for the quarter ended October 1, 2006, filed on November 3, 2006, formatted in XBRL (eXtensible Business Reporting Language): (i) the Condensed Consolidated Statements of Income for the three and nine months ended October 1, 2006 and October 2, 2005, (ii) the Condensed Consolidated Balance Sheets at October 1, 2006 and December 31, 2005, and (iii) the Condensed Consolidated Statements of Cash Flows for the nine months ended October 1, 2006 and October 2, 2005.

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.


		PFIZER INC.

		By: /s/ Margaret M. Foran
		Margaret M. Foran


Dated: December 11, 2006		Title: Senior Vice President-Corporate Governance
		Associate General Counsel and Corporate Secretary

EXHIBIT INDEX

Exhibit No.		Description

EX-100.INS		XBRL Instance Document

EX-100.SCH		XBRL Taxonomy Extension Schema Document

EX-100.SCH.1		XBRL Schema Supplement Document

EX-100.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

EX-100.LAB		XBRL Taxonomy Extension Label Linkbase Document

EX-100.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

EX-100.INS 2 pfe-20061001.xml XBRL INSTANCE DOCUMENT 0000078003 2005-10-02 unaudited 0000078003 2004-12-31 audited 0000078003 2006-07-03 2006-10-01 unaudited 0000078003 2006-01-01 2006-10-01 unaudited 0000078003 2005-07-04 2005-10-02 unaudited 0000078003 2005-01-01 2005-10-02 unaudited 0000078003 2006-10-01 unaudited 0000078003 2005-12-31 audited xbrli:shares iso4217:USD xbrli:shares iso4217:USD 1602000000 1533000000 2569000000 833000000 2446000000 798000000 6659000000 6805000000 0.57 0.19 0.72 0.24 -1527000000 -491000000 343000000 110000000 353000000 123000000 0.05 0.02 0.05 0.02 0.05 0.02 0.05 0.02 1772000000 2000000 -923000000 -845000000 -58000000 -201000000 -72000000 -37000000 44000000 3000000 23000000 3000000 5009000000 1479000000 9535000000 3239000000 299000000 107000000 330000000 120000000 3738000000 2031000000 9000000 993000000 1216000000 0 1237000000 1423000000 2497000000 2845000000 6000000 3000000 10000000 5000000 4176000000 4228000000 6521000000 5271000000 -33000000 67000000 703000000 -151000000 -958000000 -343000000 238000000 -82000000 2635000000 2782000000 2859000000 3281000000 -1493000000 -1438000000 782000000 303000000 816000000 249000000 11589000000 2508000000 510000000 460000000 346000000 593000000

9103000000

9177000000

2073000000

1742000000

479000000

1370000000

-2104000000

-1989000000

67759000000

68865000000

116970000000

108585000000

0.73

0.22

1.36

0.47

1808000000

959000000

2247000000

1177000000

485000000

579000000

439000000

441000000

5250000000

1611000000

5423000000

1962000000

28412000000

17688000000

-1088000000

-1333000000

9707000000

8838000000

0.72

0.22

1.35

0.46

-4177000000

-5211000000

-4000000

-8000000

121000000

506000000

7657000000

2012000000

11314000000

3961000000

0.67

0.20

1.30

0.44

0.68

0.20

1.31

0.45

3618000000

5209000000

26244000000

25323000000

20985000000

21051000000

5478000000

6167000000

51206000000

38873000000

116970000000

108585000000

6347000000

5561000000

-13548000000

-18846000000

2707000000

4666000000

9996000000

13118000000

5352000000

1589000000

9888000000

3362000000

-849000000

-1070000000

290000000

180000000

34858000000

11263000000

35768000000

12280000000

1424000000

1368000000

-3415000000

-4496000000

2681000000

2636000000

169000000

146000000

5000000

1051000000

108000000

22000000

6000000

3000000

23179000000

17346000000

1652000000

1390000000

513000000

16233000000

16417000000

2642000000

530000000

1769000000

717000000

-650000000

-835000000

-392000000

-118000000

-16840000000

-8472000000

-1042000000

-55000000

-5274000000

-11721000000

5287000000

1739000000

5187000000

1902000000

37608000000

43991000000

655000000

229000000

10958000000

3526000000

11027000000

3751000000

19979000000

11654000000

65764000000

69712000000

46835000000

38721000000

4143000000

4026000000

-39767000000

-44256000000

7424000000

7382000000

7306000000

7251000000

7372000000

7333000000

7275000000

7228000000

1652000000

513000000

**Condensed from audited financial statements. (a)Exclusive of amortization of intangible assets, except as disclosed in Note12B, Goodwill and Other Intangible Assets: Other Intangible Assets. EX-100.SCH 3 pfe-20061001.xsd XBRL EXTENSION TAXONOMY EX-100.SCH.1 4 pfe-ssu_xbrl.xsd XBRL SCHEMA SUPPLEMENT DOCUMENT EX-100.CAL 5 pfe-20061001_cal.xml XBRL CALCULATION LINKBASE EX-100.LAB 6 pfe-20061001_lab.xml XBRL LABEL LINKBASE Cost of sales Selling, informational and administrative expenses Other assets (including deposits and advances) deferred taxes and deferred charges Other assets, deferred taxes and deferred charges Prepaid Expenses - Total Prepaid Insurance Dividends payable represent dividends declared but not yet paid. Dividends payable Liabilities Discontinued Operations - Current Postretirement benefit obligations Accrued compensation and related items includes accrued employee compensation, accrued payroll taxes, accrued pension, accrued postemployment benefits, accrued postretirement benefits and other related items Accrued compensation and related items Represents the fair value of Pfizer Inc shares owned by the Trust used to fund Pfizer's employee benefit plans. Employee benefit trust, at fair value Income from continuing operations before provision for taxes on income and minority interests Income from discontinued operations-net of tax Income (loss) of a business segment that has been discontinued net of taxes Income/(Loss) from Disposition of Discontinued Operations - Total Cash dividends paid per common share cash dividends paid per common share Restructuring charges are associated with the exit or disposal of an activity, including one-time termination benefits, contract termination costs and other exit costs (e.g., consolidation of facilities). Merger-related costs consist of integration costs directly related to acquisitions and restructuring costs incurred in connection with acquisitions. Restructuring charges and merger-related costs Consists of other current liabilities and deferred income tax liabilities current. Other current liabilities Other (income)/deductions-net Other (income)/deductions-net can include non operating items such as interest income/expense, royalty income, asset impairments, gains/losses on sale of fixed assets, gains/losses on disposals of investments or products. income from continuing operations after provision for taxes and minority interest Income from continuing operations Net cash provided by operating activities Loss from discontinued operations loss from operations of a business segment that has been reported as discontinued operations. cash payments for purchases of property, plant and equipment Purchases of property, plant and equipment Proceeds from redemptions of short-term investments Proceeds from redemptions of long-term investments Purchases of long-term investments Acquisitions, net of cash acquired Net cash provided by investing activities Cash provided by/(used in) other investing activities, net. Other investing activities Share-based compensation expense Merger-related in-process research and development charges Asset impairment charge Other non-cash adjustments Deferred taxes from continuing operations Proceeds from the sales of businesses, products and product lines Proceeds from Short-Term Borrowings Principal payments on short-term borrowings Proceeds from issuances of long-term debt Principal payments on long-term debt Purchases of common stock Cash dividends paid cash received from stock option exercises and other financing related cash transactions not previously identified Stock option transactions and other Net cash used in financing activities Effect of exchange-rate changes on cash and cash equivalents Cash and cash equivalents at beginning of period cash paid for income taxes Cash paid during the period for income taxes Cash paid during the period for interest amortization of intangible assets Amortization of intangible assets subsidiary income not owned by the consolidating entity, net of taxes Minority interests total of operations and gains/(losses) on sales of discontinued operations. Discontinued operations-net of tax Revenues Research and development expenses Merger-related in-process research and development charges Provision for taxes on income Income/(Loss) from Disposition of Discontinued Operations Gain/(loss) on disposal of discontinued operations net of tax Gains on sales of discontinued operations - net of tax Income from continuing operations per common share-basic Income/(Loss) from Discontinued Operations per Outstanding Share Net income per common share-basic Weighted-average shares used to calculate earnings per common share-basic Income/(loss) from Disposition of Discontinued Operations per Outstanding Share Net income per common share-diluted Weighted-average shares used to calculate earnings per common share-diluted Income from continuing operations per common share-diluted Cash and cash equivalents Accounts receivable, less allowance for doubtful accounts Short-term investments Inventories Assets Discontinued Operations-Current Total current assets Property, plant and equipment, less accumulated depreciation Identifiable intangible assets, less accumulated amortization Total assets Accounts payable Income taxes payable Total current liabilities Long-term debt Pension benefit obligations Deferred taxes Other noncurrent liabilities Total liabilities Preferred stock Common stock Additional paid-in capital Treasury stock Retained earnings Accumulated other comprehensive income Total shareholders' equity Total liabilities and shareholders' equity Purchases of short-term investments Proceeds from sales of other assets Net decrease in cash and cash equivalents Depreciation and amortization Purchases of other assets Cash and cash equivalents at end of period Income/(loss) from discontinued operations per common share basic Discontinued operations-net of tax per common share-basic Income/(loss) from discontinued operations per common share diluted Discontinued operations-net of tax per common share-diluted Assets held for sale Liabilities held for sale and anticipated to be sold within 12 months. Liabilities held for sale Consists of assets of discontinued operations and long-lived assets held for sale that are expected to be disposed of or have been disposed of at the financial statement date. Assets of discontinued operations and other assets held for sale The net of new short-term borrowings with maturities of 90 days or less and new repayments of short-term borrowings with maturities of 90 days or less, and new short-term borrowings with maturities greater than 90 days. Increase in short-term borrowings, net Net income Long-term investments and loans consists of (a) investments in nonconsolidated subsidiaries accounted for using the equity and or cost method; (b) debt and equity financial instruments which can include trading securities, held-to-maturity and securities available for sale; (c) long-terms loans with maturities in excess of one year. The portion of long-term loans that is due to be collected within one year is recorded under Short-term loans Long-term investments and loans Short-term borrowings have maturities within 12 months, including portion of long-term debt with maturities within 12 months Short-term borrowings, including current portion of long-term debt Consists of liabilities of discontinued operations and other liabilities held for sale that are expected to be disposed of or have been disposed of at the financial statement date. Liabilities of discontinued operations and other liabilities held for sale Short-term loans are those with an original maturity of one year or less. Also included in this account is the portion of long-term loans that are due to be collected within one year. Short-term loans Includes Prepaid expenses and current deferred tax asset. Prepaid expenses are the unamortized costs of rights to receive a service or use a resource. These prepayments include, for example, employee advances, prepaid insurance, prepaid taxes, etc Prepaid expenses and taxes Includes minority interest and other noncurrent liabilities. Other noncurrent liabilities Gains on disposal of investments, products and product lines Gains on disposal of investments, products and product lines Non-cash gains from sales of business segment that has been reported as discontinued operations. Gains on sales of discontinued operations Noncash deferred taxes related to discontinued operations Other deferred taxes Non cash charges for intangible asset impairments and associated non-cash charges Intangible asset impairments and other associated non-cash charges Change in operating assets and liabilities from beginning to end of period. Changes in assets and liabilities (net of businesses acquired and divested) EX-100.PRE 7 pfe-20061001_pre.xml XBRL PRESENTATION LINKBASE -----END PRIVACY-ENHANCED MESSAGE-----